Addressing Alzheimers Disease Tangles: From NAP to AL-108

Author(s): Illana Gozes, Alistair Stewart, Bruce Morimoto, Anthony Fox, Karole Sutherland, Donald Schmechel.

Journal Name: Current Alzheimer Research

Volume 6 , Issue 5 , 2009

Become EABM
Become Reviewer


AL-108 is the intranasal formulation of NAP (a peptide of eight amino acids, NAPVSIPQ). Phase IIa clinical results have recently shown that AL-108 has a positive impact on memory function in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimers disease (AD). The clinical development of AL-108 has been based on extensive studies showing pre-clinical efficacy for NAP. NAP has demonstrated potent neuroprotective activity in vitro and in vivo. Its mechanism of action is thought to center on the modulation of microtubule stability in the face of outside damage. Such an effect on structures of such central importance in a broad range of cellular functions is thought to explain NAPs activity in wide ranging models of cellular damage and neurodegeneration. The following article reviews NAPs discovery and pharmacological characterization that has led to clinical development of a novel tangle-directed drug candidate.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [455 - 460]
Pages: 6
DOI: 10.2174/156720509789207895
Price: $58

Article Metrics

PDF: 9